Ambu A/S
CSE:AMBU B
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Ambu A/S
Free Cash Flow
Ambu A/S
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Ambu A/S
CSE:AMBU B
|
Free Cash Flow
kr351m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
GN Store Nord A/S
CSE:GN
|
Free Cash Flow
kr872m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-14%
|
CAGR 10-Years
4%
|
|
|
Demant A/S
CSE:DEMANT
|
Free Cash Flow
kr3.3B
|
CAGR 3-Years
24%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
|
|
V
|
ViroGates A/S
CSE:VIRO
|
Free Cash Flow
-kr5.9m
|
CAGR 3-Years
28%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
Ambu A/S
Glance View
Ambu A/S, a Danish company rooted in innovation, has carved a niche in the global healthcare sector through its specialized medical devices. Founded in 1937, Ambu started with a simple mission of improving patient care and has stayed true to that vision by continuously advancing their portfolio. The company's journey began with the invention of the resuscitator bag, a revolutionary product that remains a staple in emergency and hospital settings today. Over the years, Ambu has focused strategically on three main segments: Anesthesia, Patient Monitoring & Diagnostics, and Visualisation, each playing a crucial role in the broader healthcare ecosystem. These segments allow Ambu to develop devices that enhance diagnostic procedures, improve safety, and increase efficiency in medical settings, ultimately saving lives and optimizing healthcare delivery. Ambu’s business model capitalizes primarily on innovation-driven sales, with a strong emphasis on disposable medical devices which are gaining popularity due to hygiene concerns and regulatory trends favoring single-use technologies. These products include their flagship single-use endoscopes, marketed under the brand name "Ambu aScope," which significantly reduce the risk of cross-contamination while providing high-quality diagnostic images. The company's revenue model is built on a B2B approach, dealing directly with hospitals, clinics, and other healthcare providers, ensuring a steady flow of sales through long-term contracts and partnerships. Through constant reinvestment into R&D and strategic acquisitions, Ambu sustains its market leadership, driving growth by addressing the evolving needs of the healthcare industry and setting standards in patient care solutions globally.
See Also
What is Ambu A/S's Free Cash Flow?
Free Cash Flow
351m
DKK
Based on the financial report for Dec 31, 2025, Ambu A/S's Free Cash Flow amounts to 351m DKK.
What is Ambu A/S's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
44%
Over the last year, the Free Cash Flow growth was -23%.